No Data
OBIO and CATTI Collaborate to Boost Canada's Biomanufacturing Capacity for Advanced Therapies
The first gene therapy CDMO stock cannot break out of the loss "vortex"! HUYA Bio had a net loss of 0.19 billion in the first three quarters.
Hepalink is still deeply in the vortex of losses, with a net loss attributable to the mother of 0.19 billion yuan in the first three quarters of this year, a year-on-year decrease of 166.90%, compared to a net loss of 71.0996 million yuan in the same period last year. Hepalink revealed that customers are more price-sensitive due to lack of financing, and prices of different types of CDMO orders are at historically low levels.
Heyuan Biotech: Report for the third quarter of 2024
Third Quarter Report 2024
Hugestone Biotech (688238.SH) released its performance for the first three quarters, with a net loss of 0.19 billion yuan.
Hengyuan Biology (688238.SH) released the third quarter report for 2024, during the reporting period the company achieved revenue...
Hoyu Biotech (688238.SH): net loss of 0.19 billion yuan in the first three quarters.
Gelonghui reported its third-quarter financial results on October 23rd. The revenue was 0.18 billion yuan, a year-on-year increase of 34.22%, with a net loss of 0.19 billion yuan and a non-GAAP net loss of 0.2 billion yuan. The basic earnings per share was -0.293 yuan.
Is Obio Technology (Shanghai) (SHSE:688238) Using Too Much Debt?No Data
No Data
